Upcoming events – Axsome takes on migraine and Kala looks to dry eye again

Axsome hopes to find a niche with its migraine project, AXS-07, while Kala's latest phase III needs to win over the regulators.

Welcome to your weekly roundup of approaching clinical readouts. Axsome is due to report data by the end of the year with AXS-07 in acute migraine patients who have had an inadequate response to prior acute treatments. 

Acute migraine therapy is dominated by generic triptans; AXS-07, a combination of rizatriptan and the Cox-2 NSAID meloxicam, is essentially designed to be a better version of these older drugs. This means that Axsome is aiming for a different slice of the market than oral CGRP inhibitors, for example, which will likely be reserved for patients who do not respond to triptans or cannot take them – the drugs are linked with cardiovascular side effects.

AXS-07 uses Axsome’s MoSEIC technology, which is designed to improve drug absorption. Leerink analysts say the project could find a niche as a faster-onset version of its established components, which could help AXS-07 gain market share in the front-line setting – if its price is not a hindrance. But AXS-07 might end up with a cardiovascular warning on its label, like other triptans.

First, the project will need a win in the phase III Momentum trial. The 875-patient study is testing AXS-07 versus rizatriptan and meloxicam alone, or placebo. The co-primary endpoints are freedom from headache pain and freedom from the most bothersome migraine-associated symptom two hours after dosing, for AXS-07 compared with placebo.

Superiority of AXS-07 to the rizatriptan and meloxicam arms could be established based on sustained freedom from headache pain from two to 24 hours after dosing, and a look at historical data with rizatriptan shows what Axsome's project might need to achieve.

What AXS-07 needs to beat: rizatriptan results
% of patients reporting complete pain relief at 2hr, placebo-adjusted (NCT00897949)
Maxalt* 5mg Maxalt 10mg
23 32
*Branded rizatriptan (Merck & Co). Source: publication.

Axsome recently started another acute migraine trial of AXS-07, called Intercept, which is due to read out in the first quarter of 2020. This will evaluate treatment with AXS-07 as soon as a migraine starts, rather than waiting for the migraine to reach moderate to severe intensity, which is typical in migraine trials.

However, according to Axsome, Momentum will be the only study required for the NDA filing, which is expected in the second half of next year.

Top migraine products in 2024, excluding anti-CGRPs
    Annual indication sales ($m)  
Product Company 2018 2024e Indication status
Botox Allergan 869 1,208 Marketed
Reyvow Lilly - 365 Approved
Imitrex* Glaxosmithkline 188 129 Marketed
Qtrypta* Zosano Pharma - 111 Phase III
Migranal Bausch Health 62 55 Marketed
Amerge* GlaxoSmithKline 57 52 Marketed
AXS-07* Axsome Therapeutics - 50 Phase III
Frova* Menarini/Endo/Recordati 61 44 Marketed
Cambia Assertio Therapeutics 36 33 Marketed
XEN007 Xenon Pharmaceuticals - 33 Phase I
*Contain triptan. Source: EvaluatePharma.

Back in its Stride?

Meanwhile, after being hit by a complete response letter in August, Kala’s KP-121 needs to shine in its next phase III trial, Stride 3, with data expected in the first quarter of 2020.

The regulatory knockback was not hugely unexpected as the dry eye project, which Kala has branded Eysuvis, produced mixed results in two previous trials, with Stride 2 missing one of its co-primary endpoints, ocular discomfort. This is the sole primary endpoint of Stride 3, which will compare KP-121 0.25% with placebo. Each cohort will be dosed four times a day for two weeks in approximately 900 patients with dry eye disease.

Kala hopes that changes to the inclusion/exclusion criteria could give Stride 3 a better chance of success – the company previously said that patients in Stride 2 had variable levels of symptoms at baseline.

If Stride 3 hits a resubmission could occur in the first half of next year, followed by a six-month review, according to the company. The next challenge would be hitting sellside numbers: 2024 sales are forecast to reach $710m, and the project has an NPV of $1.5bn, according to EvaluatePharma consensus, making it Kala’s most valuable project asset.

However, the company's market cap is just $126m, so investors apparently do not share the sellside's enthusiasm.

KP-121 phase III data
  Results of primary endpoints, baseline to day 15, ITT population  
Study Sign endpoint (conjunctival hyperaemia) Symptom endpoint (ocular discomfort severity) Trial ID
Stride 1 Met p<0.0001 Met p<0.0001 NCT02813265
Stride 2 Met p<0.0001 Missed p=0.1298 NCT02819284
Stride 3 - Data due by year end NCT03616899
Source: company press release.

Share This Article